Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Fig. 4

MAGE-A3 positive peripheral CD8 cells and tumor response. a Peripheral blood flow cytometry of MAGE-A3+ CD8 T cells over time in 9 HLA-A2.1+ patients using an HLA-A2.1-restricted MAGE-A3 epitope. Patient 16 with complete response (red) shows high MAGE-A3 + CD8 cells at baseline and a robust increase in MAGE-A3 + CD8 cells early on treatment. Non-responding patients shown in black and patient with prolonged stable disease in yellow. b. Cross-sectional CT images of patient 16 who had lung metastasis at baseline, achieved a partial response at 18 months and a complete response at 32 months. White arrow indicates lung metastasis

Back to article page